# A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

> **NCT02951988** · PHASE3 · COMPLETED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 1304 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Rapastinel
- **DRUG:** Placebo-matching Rapastinel

## Key facts

- **NCT ID:** NCT02951988
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-13
- **Primary completion:** 2019-02-22
- **Final completion:** 2019-02-22
- **Target enrollment:** 1304 (ACTUAL)
- **Last updated:** 2020-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951988, "A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02951988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*